<DOC>
	<DOC>NCT02291237</DOC>
	<brief_summary>This study will evaluate the effect of eleclazine (GS-6615) on exercise capacity, quality of life, and safety and tolerability of eleclazine in participants with symptomatic hypertrophic cardiomyopathy (HCM).</brief_summary>
	<brief_title>Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
	<criteria>Key Established diagnosis of hypertrophic cardiomyopathy defined by standard criteria as a maximal left ventricular wall thickness ≥ 15 mm at initial diagnosis Exertional symptoms including at least one of the following: New York Heart Association (NYHA) Class ≥ II dyspnea Canadian Cardiovascular Society (CCS) Class ≥ II angina Screening (baseline) peak VO2 &lt; 80% of predicted for age, sex, and weight Ability to perform an upright treadmill cardiopulmonary exercise test (CPET) Key Known aortic valve stenosis (moderate or severe) Known coronary artery disease Left ventricular systolic dysfunction (ejection fraction &lt; 50%) Recent septal reduction procedure (ie, surgical myectomy or alcohol septal ablation) within six months prior to screening or such a procedure scheduled to occur during the study Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hypertrophic cardiomyopathy</keyword>
	<keyword>hcm</keyword>
	<keyword>hocm</keyword>
	<keyword>hypertrophic myocardiopathy</keyword>
	<keyword>hypertrophic obstructive cardiomyopathies</keyword>
	<keyword>cardiomyopathy</keyword>
	<keyword>hypertrophic</keyword>
	<keyword>familial hypertrophic cardiomyopathy</keyword>
	<keyword>genetic heart disease</keyword>
	<keyword>echocardiography</keyword>
	<keyword>cardiopulmonary exercise testing</keyword>
	<keyword>exercise Capacity</keyword>
	<keyword>heart failure</keyword>
	<keyword>angina</keyword>
	<keyword>dyspnea</keyword>
	<keyword>diastolic dysfunction</keyword>
	<keyword>microvascular ischemia</keyword>
	<keyword>late sodium current inhibitor</keyword>
	<keyword>GS-6615</keyword>
	<keyword>late INA</keyword>
</DOC>